Cytokinetics(NASDAQ) CYTK

Cytokinetics, Incorporated helps people with heart and muscle diseases live better lives. It makes medicines that improve how muscles work and perform. These treatments serve adults with heart conditions that make daily tasks difficult.

Pills, Pumps, and Muscle Power

• MYQORZO: Oral inhibitor of cardiac myosin approved to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM); reduces heart muscle thickening and improves exercise capacity.
• Omecamtiv Mecarbil: Late-stage cardiac myosin activator designed to target the underlying deficit of heart contractility in patients with heart failure.
• Ulacamten: Selective oral inhibitor currently in Phase 2 clinical trials for heart failure with preserved ejection fraction (HFpEF).
• CK-089: Skeletal muscle troponin activator in Phase 1 trials for muscular dystrophy and other conditions of impaired muscle function.

Recent Wins and Global Deals

• Launched MYQORZO commercially in the United States in the first quarter of 2026 following FDA approval in December 2025.
• Obtained European Commission approval for MYQORZO in February 2026 for adult patients with symptomatic oHCM.
• Entered a license agreement with Bayer in November 2024 to develop and commercialize aficamten in Japan.
• Assigned commercial rights for MYQORZO in China and Taiwan to Sanofi, with commercialization starting in the first quarter of 2026.
• Raised $760.1 million in net proceeds through a public stock offering in May 2026.

A Unique Look at Cells

Cytokinetics focuses on the biology of the cytoskeleton, which is the internal structure of human cells. This specialty allows the firm to design small molecules that specifically target muscle performance and contractility.

The Numbers on the Page

• Total revenue was $48.0 million for the six-month period ended June 30, 2026, down from $68.3 million year over year.
• Net product revenue from MYQORZO was $30.1 million for the six-month period ended June 30, 2026.
• Selling, general and administrative expenses rose $86.2 million to $209.3 million for the first half of 2026.
• Cash, cash equivalents, and marketable securities totaled $1.7 billion as of June 30, 2026.
• The company has recorded an accumulated deficit of approximately $3.9 billion since its inception.

Bottom Line

Cytokinetics has transitioned from a research firm to a commercial biopharmaceutical company with its first approved heart medication. The company continues to advance a broad pipeline of muscle-directed therapies through international partnerships and clinical development.